Skip to main content

Viatris Inc company profile

  • VTRS · Nasdaq
  • Pharmaceuticals
  • S&P 500
$20.82+0.73%Close 13 Nov 2026

About Viatris Inc

Viatris is a global healthcare company that supplies generic medicines, complex products, branded and iconic brands, and an expanding portfolio of innovative medicines. It sells to retail and pharmacy establishments, wholesalers, governments, institutions, physicians and other customers across more than 165 countries and territories. The Company operates 27 manufacturing, packaging and distribution sites, with manufacturing in locations including the U.S., Puerto Rico, Singapore, India, Australia, China and certain EU countries. It reports through four segments: Developed Markets, Emerging Markets, JANZ and Greater China. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India. Its portfolio spans more than 10 major therapeutic areas, and it has more than 1,400 approved molecules.

A summary of the business section of the company's latest annual report, filed 26 Feb 2026.

Company facts

TickerVTRS · Nasdaq
SectorPharmaceuticals
IndustryPharmaceuticals
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1792044
Latest annual report10-K, filed 26 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Scott A. SmithChief Executive Officer · Director1.3M · < 1%Shares withheld for tax, 6 Mar 2026
Brian RomanChief Legal Officer328K · < 1%Shares withheld for tax, 4 Mar 2025
Melina HigginsDirector220K · < 1%Option exercise, 6 Mar 2026
Andrew EnriettiSee Remarks220K · < 1%Option exercise, 15 Aug 2026
Mark ParrishDirector165K · < 1%Option exercise, 6 Mar 2026
James M. KiltsDirector161K · < 1%Option exercise, 6 Mar 2026
Richard MarkDirector116K · < 1%Option exercise, 6 Mar 2026
W. Don CornwellDirector112K · < 1%Option exercise, 6 Mar 2026
JoEllen Lyons DillonDirector103K · < 1%Option exercise, 6 Mar 2026
Corinne Le GoffChief Commercial Officer83.2K · < 1%Shares withheld for tax, 15 Apr 2026
Leo GroothuisDirector63.4K · < 1%Option exercise, 6 Mar 2026
Elisha FinneyDirector62.7K · < 1%Option exercise, 6 Mar 2026
Michael Severino, M.D.Director26.0K · < 1%Option exercise, 6 Mar 2026
David SimmonsDirector24.5K · < 1%Option exercise, 6 Mar 2026
Campbell PaulSee Remarks—Sale under a 10b5-1 plan, 25 Jun 2026
Mistras TheodoraChief Financial Officer—Shares withheld for tax, 6 Mar 2026
Vivaldi Coelho RogerioDirector—Option exercise, 6 Mar 2026
DAMELIO FRANK ADirector—Option exercise, 6 Mar 2026
KORMAN HARRYDirector—Option exercise, 4 Mar 2025
Malik RajivDirector—Option exercise, 4 Mar 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

VTRS in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.